Bayer reduces Q3 loss to €963 million

Bayer reported a net loss of €963 million in the third quarter, down from €4.18 billion a year earlier, driven by improved performance in its agricultural and pharmaceutical divisions, while confirming its 2025 guidance.

The company’s revenues rose 0.9% to €9.66 billion on an adjusted basis, with EBITDA before extraordinary items up 20.8% to €1.51 billion. Net financial debt slightly declined to €32.71 billion. CEO Bill Anderson highlighted the resilience of the agricultural sector and pharmaceutical sales, noting that the Consumer Health division faces tougher market conditions.

Anderson also addressed ongoing U.S. litigation, emphasizing that Bayer’s multidisciplinary strategy is on track to significantly reduce legal risks by the end of 2026. He reaffirmed confidence in the company’s ability to achieve its revised 2025 targets, supported by steady operational performance and strategic measures across divisions.